ERBB2 and breast cancer: Achieving pCR is an established favorable prognostic sign but—as a reflection of the heterogeneous nature of breast cancer—the fraction of pCR varies greatly in patient subgroups ranging from 50–80% in Her2-amplified to 5–20% in luminal BC [28].